Table 5.
Univariate and multivariate Cox proportional hazards model to predict progression-free survival in cervical cancer treated with CCRT
| Variables | Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Age (as continuous variable) | 0.99 (0.96–1.03) | 0.51 | |||
| BMI (as continuous variable) | 0.95 (0.82–1.08) | 0.42 | |||
| Tobacco use | No vs Yes | 0.57 (0.13–1.69) | 0.33 | ||
| Alcohol use | No vs Yes | 0.87 (0.26–2.48) | 0.87 | ||
| Diabetes | No vs Yes | 1.54 (0.44–4.18) | 0.46 | ||
| FIGO stage | IB2, IIA2 vs IIB, IIIA | 4.30 (0.82–79.07) | 0.09 | ||
| vs IIIB, IVA | 2.31 (0.44–42.52) | 0.37 | |||
| Hydronephrosis | No vs Yes | 1.37 (0.31–3.93) | 0.67 | ||
| Histologic type | SCC vs Adenocarcinoma | 3.32 (1.12–8.44) | 0.03 | 3.55 (1.22–9.23) | 0.02 |
| Maximum tumor diameter (as continuous variable) | 1.49 (1.17–1.84) | <0.01 | |||
| Maximum tumor diameter | ≤40 vs >40 mm | 3.82 (1.29–16.38) | 0.01 | 4.93 (1.60–21.72) | <0.01 |
| Pretreatment hemoglobin (as continuous variable) | 0.70 (0.52–0.93) | 0.01 | |||
| Pretreatment hemoglobin | ≥11 vs <11 g/dl | 2.72 (1.12–6.49) | 0.03 | 3.22 (1.34–8.13) | 0.01 |
| Pelvic lymph node metastases | Negative vs Positive | 2.22 (0.93–5.35) | 0.07 | ||
| Pretreatment SCC Ag (as continuous variable) | 1.01 (0.99–1.02) | 0.18 | |||
| Pretreatment CEA (as continuous variable) | 1.02 (0.97–1.06) | 0.43 | |||
| Overall treatment time (as continuous variable) | 1.00 (0.95–1.04) | 0.91 | |||
CCRT = concurrent chemoradiotherapy, BMI = body mass index, FIGO = International Federation of Gynecology and Obstetrics, SCC = squamous cell carcinoma, SCC Ag = squamous cell carcinoma antigen, CEA = carcinoembryonic antigen, HR = hazard risk, CI = confidence interval.